Company Filing History:
Years Active: 2021
Title: Andrew Kelley Evans: Innovator in Adrenergic Receptor Modulation
Introduction
Andrew Kelley Evans is a notable inventor based in Essex Junction, VT (US). He has made significant contributions to the field of pharmacology, particularly in the development of adrenergic receptor modulating compounds. His work focuses on innovative methods for treating diseases associated with adrenergic receptors.
Latest Patents
Andrew Kelley Evans holds a patent for "Adrenergic receptor modulating compounds and methods of using the same." This patent outlines compounds and methods that can be used to treat conditions related to adrenergic receptors. The invention includes methods for modulating inflammatory pathways in cells, such as the production of TNF-alpha. The patent emphasizes the use of β1-selective adrenergic receptor modulating compounds to selectively activate a cAMP pathway over a beta-arrestin pathway in cells. Additionally, pharmaceutical compositions and kits containing these compounds are also provided.
Career Highlights
Andrew Kelley Evans is affiliated with Leland Stanford Junior University, where he continues to advance research in his field. His innovative work has led to the development of new therapeutic strategies that could significantly impact patient care.
Collaborations
Throughout his career, Andrew has collaborated with esteemed colleagues, including Mehrdad Shamloo and Alam Jahangir. These partnerships have fostered a collaborative environment that enhances research and innovation.
Conclusion
Andrew Kelley Evans is a prominent figure in the realm of adrenergic receptor modulation, with a patent that showcases his innovative approach to treating related diseases. His contributions to pharmacology and collaboration with other researchers highlight the importance of teamwork in advancing scientific knowledge.